Company Overview - Alnylam Pharmaceuticals, Inc. is a leading player in the biopharmaceutical industry, focusing on RNA interference (RNAi) therapeutics aimed at silencing specific genes associated with various diseases [1] - The company competes with other biotech firms such as Moderna and BioNTech, positioning itself among the leaders in the sector [1] Recent Developments - On September 5, 2025, Kostas Biliouris from BMO Capital set a price target of $470 for ALNY, indicating a potential upside of about 3.8% from its trading price of $452.81 at that time [2] - Alnylam participated in Citi's Biopharma Back to School Conference on September 3, 2025, where key executives discussed the company's strategic initiatives and future plans [3] Stock Performance - Currently, ALNY's stock is priced at $452.13, reflecting a slight decrease of 0.31% or $1.41, with a daily trading range between $444.66 and $455.05 [4] - Over the past year, ALNY has experienced significant volatility, with a high of $469.81 and a low of $205.87 [4] Market Position - Alnylam's market capitalization is approximately $59.26 billion, indicating a substantial presence in the market [5] - The stock has a trading volume of 264,290 shares on the NASDAQ exchange, highlighting active trading and investor interest in Alnylam's growth potential [5]